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The pathophysiology of negative affect states in older adults is complex, and a host of central nervous system and peripheral
systemic mechanisms may play primary or contributing roles. We conducted an unbiased analysis of 146 plasma analytes in
a multiplex biochemical biomarker study in relation to number of depressive symptoms endorsed by 566 participants in the
Alzheimer’s Disease Neuroimaging Initiative (ADNI) at their baseline and 1-year assessments. Analytes that were most highly
associated with depressive symptoms included hepatocyte growth factor, insulin polypeptides, pregnancy-associated plasma
protein-A and vascular endothelial growth factor. Separate regression models assessed contributions of past history of
psychiatricillness,antidepressantor other psychotropic medicine, apolipoprotein Egenotype,body mass index, serum glucose
and cerebrospinal ﬂuid (CSF) s and amyloid levels, and none of these values signiﬁcantly attenuated the main effects of the
candidate analyte levels for depressive symptoms score. Ensemble machine learning with Random Forests found good
accuracy (B80%) in classifying groups with and without depressive symptoms. These data begin to identify biochemical
biomarkers of depressive symptoms in older adults that may be useful in investigations of pathophysiological mechanisms of
depression in aging and neurodegenerative dementias and as targets of novel treatment approaches.
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Introduction
The prevalence and incidence of clinically signiﬁcant depres-
sive symptoms increase with advancing age, especially
among those with physical illness, cognitive decline and
functional disability.
1–3 In community-dwelling seniors, the
prevalence of major depression is B10%, whereas the rate
for ‘minor’, ‘subsyndromal’ or ‘subthreshold’ depression is
B30%, but may be as high as 48% among those 475 years.
Subsyndromal depression is not benign as it carries clinically
signiﬁcant disability, poorer quality of life and higher health-
care costs.
1,4
The pathophysiology of late-life depression is complex,
and a host of central nervous system and peripheral systemic
mechanisms may play primary or contributing roles.
Age-associated neurological illnesses such as Alzheimer’s
disease (AD), stroke and Parkinson’s disease are well-known
risk factors and may be associated with depression due
to disruption of neural circuitries that mediate the experience
and expression of negative emotions and behaviors by
their deﬁned neuropathological lesions and neurochemical
changes.
5–7 Cardiovascular disease, inﬂammatory condi-
tions, cancer, metabolic and endocrine dysfunction also
increase with age and are highly associated with depression.
They are commonly thought to exert their effect via circulating
factors such as inﬂammatory markers produced in the course
of these chronic disease processes, although evidence to
support this is still controversial.
8–11 Numerous hypothesis-
based studies of depression in adulthood and late life have
identiﬁed associations with glucocorticoids and other stress
hormones,
12 insulin resistance,
13 inﬂammatory cytokines and
chemokines
14 and trophic factors
15–17 that may be activated
with normal and abnormal aging processes and/or in
response to illness, injury and other stressors, although the
data in older adults for all of these are relatively scarce.
Whether alterations in these various age- and depression-
associated factors are causative of depression or conse-
quences thereof and how they interact are not established.
The identiﬁcation and validation of biomarkers in psychiatry
has been challenging but the task remains important to both
better understand the pathophysiology of depression and
better classify and treat this multifactorial syndrome in an era
of personalized medicine. Here, we used data from a large
multianalyte biochemical panel in plasma samples from older
adult participants in the Alzheimer’s Disease Neuroimaging
Initiative (ADNI) in a discovery analysis to identify peripheral
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www.nature.com/tpbiochemical biomarkers that associate with depressive
symptoms. Our ﬁndings provide further support for a role of
several previously identiﬁed proteins in negative affect states
and identify novel candidates for validation and investigation
in future studies and other cohorts.
Subjects and methods
Description of the ADNI. The ADNI is a large, multicenter,
longitudinal neuroimaging and biomarker study, launched in
2004,
18–20 with a primary goal to characterize cognitive
functioning and AD in older adults with longitudinal clinical
assessments, multiple modality neuroimaging and blood,
urine and cerebrospinal ﬂuid (CSF) molecular and bio-
chemical biomarkers. Participants received baseline and
periodic physical and neurological examinations, standar-
dized neuropsychological assessments, apolipoprotein E
(APOE) genotyping and they provided bioﬂuid samples
throughout the study.
21,22 Imaging (magnetic resonance
imaging and for a subset,
18F-ﬂuorodeoxyglucose positron
emission tomography and
11C-Pittsburgh compound B
positron emission tomography) is performed at baseline
and at regular intervals thereafter.
20 The procedures for this
study were approved by institutional review boards of all
participating institutions. All subjects gave written, informed
consent for all procedures before participation.
Participants. The total ADNI cohort includes 819 older
adults, 55 to 90 years old, who met entry criteria for a clinical
diagnosis of normal cognition, amnestic mild cognitive
impairment (MCI) or probable AD.
19 Participants with AD
met National Institute of Neurological and Communication
Disorders/Alzheimer’s Disease and Related Disorders
Association criteria for probable AD and had a Mini-Mental
State Examination score between 20 and 26 and a global
Clinical Dementia Rating (CDR) of 0.5 or 1.0 and, therefore,
were only mildly impaired at baseline. Inclusion criteria for
participants with MCI included memory complaint and
abnormal memory score on the Wechsler Memory Scale,
Mini-Mental Sate Examination score between 24 and 30
and a CDR of 0.5 with a Memory Box score of at least 0.5.
People with signiﬁcant current psychiatric illness were
ineligible to participate in ADNI and thus only participants with
no more than mild depression, anxiety or other symptoms
were enrolled. Speciﬁc exclusion criteria for all participants
included major mood disorder within a year of screening, a
score of X6 on the Geriatric Depression Scale (GDS),
23,24
history of schizophrenia, alcohol or substance abuse within
the past 2 years, and for AD and MCI participants, any
psychosis, agitation or behavior problems. For a review and
more details on inclusion and exclusion criteria, see Mueller
et al.
25 and http://www.adni-info.org/.
The multi-analyte biochemical panel assays used here
were conducted in a subsample of 566 ADNI participants,
including 396 with MCI, 112 with AD and 58 with normal
cognition. Subsampling was necessary because of budgetary
constraints. Samples were selected to enrich for MCI cases
and cases with additional biomarker end points (for example,
CSF amyloid-b and -t and amyloid neuroimaging) to be used
in separate analyses. Table 1 presents demographic and
clinical characteristics of the sample used here.
Assessments of depression and cognition. The primary
outcome measure of depressive symptoms was the
short version of the GDS.
26 This 15-item self report form
has demonstrated robust validity for depression in older
adults,
24,26 including those with MCI,
27 although its reliability
may diminish in people with dementia.
28 One item in the GDS
asks if the subject feels he/she has more memory problems
than most. Given the frequency of memory complaints in
ADNI, this item was excluded from the total score that was
used in analyses here.
The ADNI protocol includes a comprehensive assessment
of cognitive functioning with particular emphasis on domains
relevant to AD. A full description is available at http://
www.adni-info.org/Scientists/CognitiveTesting.aspx. Clinical
data from the baseline and 12-month assessments were
used. To control for potentially confounding effects of
cognitive syndrome on outcome measures of depression in
participants with AD, MCI and normal cognition, the CDR
Sum-of-Boxes score was included as a covariate in statistical
analyses.
29 The CDR is a structured interview assessing
functional status in the domains of memory, orientation,
judgment and problem solving, home and hobbies and
personal care.
Plasma sampling and biochemical multi-analyte panel.
Morning fasting plasma samples were obtained at baseline
and 12-month assessments. Whole-blood samples were
obtained in EDTA tubes, placed immediately on ice, spun
down for plasma aliquoting and frozen at  801C, per ADNI
lab standard operating protocols as reviewed recently.
30
Plasma samples from the ADNI biospecimen repository at
the University of Pennsylvania were sent to Rules-Based
Medicine (RBM, Austin, TX, USA) for measurement of 190
protein analytes with a multiplex immunoassay panel. This
panelwasdevelopedontheLuminexxMAP(Austin,TX,USA)
platform to measure proteins previously reported to be altered
in cancer, cardiovascular disease, metabolic disorders and
inﬂammation. RBM also included additional analytes believed
to be involved in cell signaling and previously reported to
change in patients with AD.
31 RBM has attempted to validate
each of the 190 analytes up to CLIA (Clinical Laboratory
Improvement Amendment) standards, but the assays them-
selves are not CLIA approved. Each analyte has an individual
standard curve with between 6 and 8 reference standards.
Each plate is run with three levels of quality control (QC)
measures (low, medium and high dilutions). Each analyte has
a validation report, including a dynamic range in young adults.
Additional QC measures for almost all analytes were
employed speciﬁcally for the ADNI plasma analysis by testing
blank human plasmas spiked with extracts of cell cultures
expressing the individual analytes. Samples from the total
ADNI plasma cohort were run on 15 plates.
APOE genotyping. DNA was extracted from blood using
commercial reagents (FlexiGene, Qiagen, Valencia, CA,
USA). Two single-nucleotide polymorphisms (rs7412 and
rs429358) in APOE were typed using allelic discrimination
Biomarkers of depressive symptoms in older adults
SE Arnold et al
2
Translational Psychiatryassays with TaqMan reagents (Applied Biosystems, Foster
City, CA, USA) on an ABI 7500. The APOE genotypes (e2, e3
and e4) were assigned by incorporating the genotyping
results into an algorithm.
Statistical analyses and machine learning analyses.
Analyses were conducted in the ‘ADNI Plasma QC
Multiplex’ data set available for download at https://ida.
loni.ucla.edu/login.jsp?project¼ADNI. This data set contains
the cleaned, quality-controlled data as described in the ADNI
statistical analysis plan. Missing, ‘LOW’ or outlier values
were imputed respectively as the mean of the nonmissing
values, half the least detectable dose, or by a nearest
neighbor or similar algorithm. Analytes for which missing/
’LOW’ values were 425% of all samples were excluded,
resulting in valid data for 146 of the total 190 analytes on the
original panel.
Linear regression models evaluated the association of
levels of each protein to GDS scores at baseline and month
12. Mixed-effect models examined if each protein is asso-
ciated with change of depression symptoms by examining the
interaction between follow-up time and each protein.
32 This
statistical procedure accounts for the correlations that are
due to repeated measurements of depression symptoms in
the same patient. All models adjusted for age, sex, education
and CDR Sum-of-Boxes score as covariates. Analyses were
conducted in SPSS Statistics 19 (IBM, Somers, NY, USA),
SAS version 9.2 (SAS Institute, Cary, NC, USA) and JMP
8.0.1 (SAS). Secondary analyses incorporated terms for past
depression or other psychiatric illness, antidepressant use
and APOE genotype. All statistical tests were two sided. We
did not conduct multiple testing adjustments except lowering
the signiﬁcance level to 0.01 and the ‘trend’ level to 0.05
because the current analyses are discovery in nature.
Consequently, there is a chance of false discovery because
of the number of statistical tests performed.
Finally, to assess the utility of such multiplex immuno-
assays as biomarker classiﬁers of depressive symptoms, we
applied a machine learning ensemble classiﬁcation method,
Random Forests (using R package RandomForest, version
4.6-2;http://www.stat.berkeley.edu/~breiman/RandomForests/
cc_home.htm). The samples were dichotomized into those
with depressive symptoms (GDS X2) versus those without
depressive symptoms (GDS¼0), with GDS¼1 serving as a
buffer. Analytes were ﬁrst sorted by z-score (derived from
variable importance score) obtained from Random Forests.
The higher the score, the more signiﬁcant the analyte is for
discriminating between samples with and without depressive
symptoms. The ﬁrst selected analyte has the highest
importance. This is then combined with all remaining analytes
to ﬁnd the second analyte, which in combination with the
ﬁrst one gives the best Out-of-Bag error estimation (used
for deriving accuracy). Finally, to gauge the robustness of
analytes’associationwithdepressivesymptoms,weapplieda
ﬁvefold cross-validation procedure to the analytes selected
by Random Forests. In each of the ﬁve validations, 80% of
the subjects were chosen for training and the remaining 20%
were used for testing; the partition was done randomly while
preserving the ratio of samples from the two categories. The
procedure was repeated three times.
Results
Of the 566 ADNI participants for whom at least baseline
plasmas were analyzed, 165 (29.2%) had depressive
symptoms (GDS 2–5) at baseline. In the subsequent year,
there were some generally modest changes in GDS scores
with a small increase in the proportion of participants with
depressive symptoms (32.1% with GDS X2 at month 12).
This included 21 participants (4.1%) whose GDS scores
increased into a more signiﬁcant category of syndromal
depression (X6, range 6–12).
Table 1 Demographic and clinical data for ADNI plasma biomarker cohort
Variable (at baseline) All Normal MCI AD Test statistic P-value
n 566 58 396 112
Demographic
Age 74.8 (7.5, 54.8–90)
a 75.1 (5.8, 62–90) 74.6 (7.4, 54.8–89.6) 74.8 (8.1, 54.8–88.8) F(2,563)¼0.06 0.94
Sex (% female) 62.0% 51.7% 64.6% 58.0% X
2(2)¼4.48 0.10
Education 15.6 (3.0, 4–20) 15.6 (2.7, 8–20) 15.7 (3.0, 4–20) 15.1 (3.2, 4–20) F(2,563)¼1.51 0.22
APOE genotype (% e4+) 51.6% 8.6% 53.3% 67.9% X
2(2)¼62.1 o0.0001
Modiﬁed Hachinski 0.63 (0.70, 0–4) 0.64 (0.79, 0–3) 0.62 (0.70, 0–4) 0.65 (0.68, 0–3) F(2,563)¼0.07 0.93
Psychiatric
Geriatric Depression
Scale (GDS-memory)
1.0 (1.2, 0–5) 0.8 (1.2, 0–4) 1.1 (1.3, 0–5) 1.1 (1.2, 0–5) F(2,563)¼1.71 0.18
Current or past psychiatric
illness (%)
33.6% 19.0% 32.0% 46.4% X
2(2)¼14.4 0.0007
Antidepressant use (%) 27.9% 6.9% 26.2% 44.6% X
2(2)¼31.2 o0.0001
Cognitive
MMSE 26.5 (2.4, 20–30) 28.9 (1.2, 25–30) 27.0 (1.8, 23–30) 23.59 (1.9, 20–27) F(2,563)¼227.7 o0.0001
ADAS-Cog total 12.3 (5.8, 1.7–42.7) 6.2 (2.8, 1.7–14.3) 11.5 (4.4, 2–27.7) 18.3 (6.4, 8.67–42.67) F(2,563)¼142.9 o0.0001
CDR Sum of Boxes 3.0 (1.6, 1–10) 1.0 (0.2, 1–2) 2.6 (0.9, 1–6) 5.3 (1.6, 2–10) F(2,563)¼415.0 o0.0001
Abbreviations: AD, Alzheimer’s disease; ADAS-Cog, Alzheimer’s Disease Assessment Scale-Cognitive Subscale; ADNI, Alzheimer’s Disease Neuroimaging
Initiative; APOE, apolipoprotein E; CDR, Clinical Dementia Rating; MCI, mild cognitive impairment; MMSE, Mini-Mental Sate Examination.
aMean (s.d., range).
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Translational PsychiatryThere were no signiﬁcant differences in age, gender or
education among the normal, MCI and mild AD diagnostic
groups at baseline. As expected, these groups differed in
frequency of APOE genotype and in measures of cognition.
Interestingly, although the diagnostic groups did not differ in
GDS scores at baseline, there were highly signiﬁcant
differences in the frequency of past psychiatric illness, with
MCI and AD participants respectively having B1.5-fold and
2.5-fold higher frequencies than those categorized as normal.
Linear regression models determined the statistical
strengths of associations of analytes with depressive symp-
toms at baseline and at month 12. The top analytes are
presented in Table 2 and statistics for the associations of all
146 plasma analytes with the main outcomes of interest are
presented in the Supplementary Table S1. Associations were
particularlystrongforhepatocytegrowthfactor(HGF),several
forms of insulin, pregnancy-associated plasma protein A
(PAPPA), and vascular endothelial growth factor (VEGF).
To examine potentially confounding effects of other vari-
ables in the associations of the top analytes, we used
separate linear regression models with additional terms for
past history of psychiatric illness, antidepressant use, use of
any psychotropic medicine, modiﬁed Hachinski Ischemic
Score,
33 APOE genotype, body mass index and serum
glucose (baseline only). The associations were essentially
the same (data not shown).
We also tested whether depressive symptoms were
related to molecular signatures of AD pathology and whether
these moderated the signiﬁcant associations of depressive
symptoms with biochemical analytes from the multi-
analyte panel. We found no associations between baseline
GDSscoresandCSFtotalt(F¼2.06,d.f.¼5,351,P¼0.15),
p-t181 (F¼2.03, d.f.¼5, 351, P¼0.15), or Ab (F¼0.89,
d.f.¼5, 351, P¼0.35), and no modifying effects.
Random Forest analyses were performed as a complemen-
taryanalyticapproachtoassesstheabilityofsetsofanalytesto
classify participants into those with (GDS X2) or without
(GDS¼0) depressive symptoms. The set of analytes was ﬁrst
selected based on z-scores obtained from Random Forests.
The ﬁnal sets of analytes were then selected with the aim of
obtaining the best classiﬁcation accuracy. Two sets of
experiments were performed on each of the baseline and
month-12 data. At baseline, 140 people with depressive
symptoms were compared with 225 with none. At month 12,
158 people had depressive symptoms whereas 210 had none.
At baseline, the best set of analytes achieved an overall 75.4%
accuracy in classifying presence or absence of depressive
symptomswithasensitivityof62.8%andaspeciﬁcityof83.8%.
At month 12, accuracy was 80.9% with a sensitivity of 59.5%
and a speciﬁcity of 94.2%. The analytes selected by Random
Forests at each assessment are presented in Table 3.
Finally,asa third approachto identify candidatebiomarkers
that may be pathophysiologically relevant to depressive
symptoms, we used mixed-effects models to discern baseline
plasma analytes that were associated with change in depres-
sive symptoms from baseline through month 24. Adjusted for
Table 2 Analytes associated with depressive symptoms
a
Baseline Month 12
Analyte at baseline
a Statistics
b (d.f.¼5,560) Analyte at month 12
a Statistics
b (d.f.¼5,489)
Hepatocyte growth factor F¼10.18, P¼0.0015 Osteopontin F¼14.22, P¼0.0002
C-peptide F¼7.91, P¼0.0051 Thyroxine-binding globulin F¼7.56, P¼0.0062
Pregnancy-associated plasma protein A F¼7.58, P¼0.0061 Tamm–Horsfall urinary glycoprotein F¼7.53, P¼0.0063
Haptoglobin F¼7.42, P¼0.0067 Hepatocyte growth factor F¼7.43, P¼0.0066
Proinsulin-total F¼7.18, P¼0.0076 Eotaxin-1 F¼6.87, P¼0.0090
Pulmonary and activation-regulated chemokine F¼6.10, P¼0.0138 Vascular endothelial growth factor F¼6.58, P¼0.011
Proinsulin-intact F¼5.88, P¼0.0156 a2-macroglobulin F¼6.21, P¼0.013
Insulin F¼4.98, P¼0.0264 Monokine induced by g-interferon F¼5.92, P¼0.015
Vascular endothelial growth factor F¼4.96, P¼0.0264 Transferrin F¼5.73, P¼0.017
Apolipoprotein (a) F¼4.60, P¼0.0325 Peptide YY F¼5.64, P¼0.018
Apolipoprotein D F¼4.00, P¼0.046 Pregnancy-associated plasma protein A F¼5.44, P¼0.020
Chromogranin A F¼5.44, P¼0.020
Trefoil factor 3 F¼4.33, P¼0.038
aAnalytes with Po0.05 are presented in rank order of P-values.
bLinear regression models with adjustment for age, gender, education and Clinical Dementia Rating (CDR) Sum of Boxes.
Table 3 Top analytes for discriminating between subjects with and without
depressive symptoms using random forest models
Baseline Month 12
Analyte
a Analyte
a
a1-Antitrypsin a1-Antichymotrypsin
Adiponectin Adiponectin
Apolipoprotein A-IV a1-Antitrypsin
Apolipoprotein E AXL receptor tyrosine kinase
Brain-derived neurotrophic factor CD40 antigen
Clusterin Complement C3
Epithelial-derived neutrophil-
activating peptide
Intercellular adhesion
molecule 1
Immunoglobulin A Interleukin-8
Insulin Macrophage colony-
stimulating factor 1
Leptin Matrix metalloproteinase-2
Myeloid progenitor inhibitory
factor 1
Peptide YY
Myoglobin Pregnancy-associated
plasma protein A
Proinsulin
Testosterone
Tumor necrosis factor
receptor-like 2
von Willebrand factor
aThe analytes are in alphabetical order.
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change of depression symptoms was associated with three
baseline analytes at the Po0.01 level, including angiopoietin
2,FAS ligand receptor and fatty acid-binding protein, and nine
at the Po0.05 level, including HGF (see Supplementary
Table S1 for statistical results for all analytes).
Discussion
Our data identiﬁed candidate plasma biomarkers of depres-
sive symptoms in older adults, which may prove useful in
investigations into the pathophysiology of negative affect
across the lifespan. Previous biomarker studies of depression
have focused on contemporaneous conceptualizations of
depression pathophysiology.
12–17,34–36 Here, we used an
unbiased multiplex discovery interrogation of 146 known
plasma analytes in a large cohort of well-characterized
subjects. In particular, HGF, insulins, PAPPA and VEGF
were identiﬁed as among the more robust and interesting
candidates.
HGF (also known as scatter factor and hematopoietin A) is
a 103kDa heterodimeric protein ﬁrst identiﬁed as a regenera-
tion factor for hepatocytes after liver injury.
37 It is a multi-
functional trophic factor that signals through a tyrosine kinase
signaling cascade after binding to MET, its proto-oncogenic
receptor. HGF is produced by neurons and non-
neuronal cells, whereas MET is especially highly expressed
in neurons. During embryogenesis, HGF is a neural inducer,
an interneuron motogen, an axonal chemoattractant, an
angiogenic factor and a neuroprotective survival factor.
38,39
Its expression continues in adulthood and it is induced by
ischemic injury
40 and other disease processes, including
AD.
41 HGF enhances long-term potentiation,
42 improves
or attenuates ischemia-related memory deﬁcits
43 and Ab-
induced behavioral impairment,
44 and has anxiolytic proper-
ties,
45 whereas its suppression increases anxiety and
depressive behaviors in rodents.
46 To our knowledge, only
two studies have investigated HGF in relation to depression in
humans, one of which found signiﬁcantly lower serum HGF
levels among 26 people with major depression compared with
19 controls,
47 whereas the other study found no difference in
HGFlevelsin12womenwithmajordepressionandborderline
personality disorder.
48 Higher serum levels of HGF have also
been found in those patients with panic disorder who best
responded to antidepressant medication.
49 To this literature,
we add our ﬁnding of an increase in plasma HGF levels with
increasing depressive symptoms in older adults. Given the
generally salutary effects of HGF, we speculate that such
an increase may represent a compensatory mechanism in
the setting of other depression-inducing pathophysiological
mechanisms.
Depressive symptoms were positively associated with
levelsofinsulinpolypeptides, insupportofa growingliterature
linking insulin resistance to depression.
13,50–53 The nature of
this association is complex as some evidence indicates a
bidirectionalrelationship;thatis,depressionincreasestherisk
for subsequent development of type 2 diabetes mellitus,
54
whereas the presence of type 2 diabetes mellitus increases
risk for incident depression.
52 One mechanism that has been
proposed to account for insulin resistance in depression is
dysregulation of the hypothalamic–pituitary–adrenal axis with
abnormal circulating levels of glucocorticoids.
12,55 Others
have invoked the effects on insulin signaling by inﬂammatory
cytokines
14 and some trophic factors
15–17 that may also be
activated in depression. Conversely, insulin activates diverse,
multifunctional signaling cascades (for example, Akt and
glycogen synthase kinase 3) that are believed to play
important roles in mood.
56,57
As further support for an insulin link to depression, we
observed an association of PAPPA with depressive symp-
toms. PAPPA is a secreted metalloproteinase that cleaves
insulin-like growth factor-binding proteins, increasing their
bioavailability.
58Toourknowledge,itsexpressionoractivityin
the brain have not been studied.
VEGF was also found to be elevated in relation to
depressive symptoms in the ADNI cohort. Previous studies
have reported VEGF gene polymorphisms associated with
major depression,
59,60 increased leukocyte VEGF mRNA
expression in refractory depression
61 and increased serum or
plasmaVEGFlevelsindepressionintwostudies
48,62butnota
third one.
63 VEGF (speciﬁcally VEGF-A measured here) is a
232-amino-acid protein with multiple isoforms that bind to
three high-afﬁnity receptor tyrosine kinases. It is widely
expressed and is best known for its growth factor activity in
angiogenesis, vasculogenesis and endothelial cell growth.
64
Analogous to insulin, after binding to its receptors, VEGF
activates numerous downstream signaling proteins including
protein kinase C, phospholipase C-g, phosphatidylinositol
3-kinase, Akt and mammalian target of rapamycin. VEGF
increases the permeability of the blood–brain barrier,
65
facilitates neurogenesis and proliferation of neurons in the
adult hippocampus,
66 plays a role in synaptic neurotransmis-
sion
67 and synaptic plasticity in hippocampus-dependent
learning and memory
68 and has anxiolytic and antidepressant
activity in rodent models.
66
Ourdatashouldbeinterpretedinlightofthestrengthsofthe
ADNI study design as well as its weaknesses. Foremost, the
ADNI study incorporates an extraordinary array of biomarker
approaches that characterize many aspects of the functional,
anatomic, physiological, biochemical and molecular health
of the aging brain. It is longitudinal, thus allowing both
cross-sectional and dynamic monitoring of phenomenology
and biology that may better elucidate disease processes.
Future analyses will investigate the relationships of bio-
chemical biomarkers of depressive symptoms identiﬁed here
in relation to other neuroimaging and longitudinal outcome
data.
On the other hand, the principal outcome of interest of
the ADNI is cognitive functioning, not emotional functioning,
and its clinical assessments of mood and other psychiatric
symptoms are limited. The assessment of depressive
symptoms is by the interviewer-administered GDS with the
research participant, and thus may lack the depth and
accuracy of a structured psychiatric interview or observer
ratings. Although the GDS is among the most well-validated
and widely used scales for depressive symptoms in the
elderly, its sensitivity wanes in people with dementia in
comparison with other ‘gold-standard’ expert rater-based
scales of depression in dementia.
27 As well, ADNI was
designed to recruit older adults who are typical of participants
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function unconfounded by depression or other illnesses that
are common in general older populations. Indeed, eligibility in
ADNI was restricted to participants with no active psychiatric
illness and no more than very mild depressive symptoms at
baseline. Despite these limitations, the sample size and
expanding range of depressive symptoms over time did allow
us to discern candidate biomarkers of depressive symptoms
that are also biologically plausible. However, given the
exclusion of subjects with any clinically signiﬁcant depression
at the time of enrollment in ADNI, it is important to recognize
that our analyses may have failed to detect depression-
related analytes that would be found in people with more
severe symptoms or that our ﬁndings may be speciﬁc only to
subsyndromal depressive symptoms in older adults and not
major or minor depression in general.
There have been very few biomarker discovery investiga-
tions of psychiatric disorders that employ multi-analyte panels
such as ours. Simon et al.
69 tested a chronic inﬂammation
hypothesis of major depressive disorder using a 22-plex
cytokine/chemokine panel on a Luminex platform in 49
patients and 49 controls and found signiﬁcant differences in
most of the analytes, thus supporting their hypothesis. More
recently, Domenici et al.
70 used a 79-plex analyte panel from
RBMto proﬁle plasmas from 245 patientswith recurrent major
depressive disorder, 229 patients with schizophrenia and
254 nonpsychiatric controls. Many of the analytes in their
panel were also measured in ours. In univariate analyses,
the analyte that showed the greatest difference between
depressed and control groups was insulin.
There is substantial evidence that higher levels of inﬂam-
matory biomarkers, such as tumor necrosis factor-a, various
interleukins and transforming growth factor-b are present in
major depression as well as AD.
71,72 Our analyses did not ﬁnd
any association between depressive symptoms and
these inﬂammatory cytokines. However, it is important to
again note the differences in subjects used in these studies,
where ADNI speciﬁcally excludes participants with major
depression.
There is growing recognition that chronic psychological
distress is a risk factor for cognitive decline and aging-related
dementias.
73–76 Consonant with this, we observed a 41.5-
fold higher rate of past psychiatric illness among ADNI
participants with MCI at baseline and an almost 2.5-fold
higher rate in those with AD compared with those with normal
cognition. The mechanism(s) by which depression and other
facets of psychological distress increase dementia risk is not
clear. Overall, post-mortem clinicopathological studies have
not found associations between psychological distress and
the deﬁning pathologies of neurodegenerative dementias
such as Ab plaque or neuroﬁbrillary t tangle densities,
a-synuclein Lewy bodies or cerebral infarcts.
77,78 Here as
well, we saw no association between CSF t or Ab levels (as
proxies for brain AD pathology) and depressive symptoms.
Thus, it will be important to further investigate the candidate
biomarkersassociatedwithdepressivesymptomsidentiﬁedin
this study for their relationship to subsequent cognitive
decline, to neuroimaging evidence of atrophy and other
evidence of neurodegeneration and to post-mortem neuro-
pathological ﬁndings as these become available.
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